Metformin for neurocognitive dysfunction in schizophrenia: a systematic review.

ABSTRACT:

Background

The efficacy and safety of metformin for addressing neurocognitive dysfunction in schizophrenia remain inconclusive. This systematic review evaluates the evidence from randomized controlled trials (RCTs) on the effects of metformin on neurocognitive function in patients with schizophrenia.

Methods

A comprehensive search of Chinese databases (WanFang, Chinese Journal Net) and English databases (PubMed, EMBASE, PsycINFO, and Cochrane Library) was conducted to identify RCTs assessing metformin's impact on neurocognitive outcomes in schizophrenia.

Results

Four RCTs involving 271 patients with schizophrenia were included. Three RCTs (75%) demonstrated significant improvements in neurocognitive function with metformin compared to controls, as assessed by the MATR

SUBMITTER: Qin ZJ 

PROVIDER: S-EPMC11788895 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature